Indium-111-labeled autologous leukocytes in man.
Autologous leukocytes have been isolated, labeled with indium-111, and administered to 15 patients suspected of inflammatory disease. The stability of the label has been demonstrated and the in vivo kinetics and distribution of the labeled cells studied. The distribution is influenced by the type and viability of the cells separated by three different techniques. Generally, there was initial accumulation of radioactivity in the lungs; approximately half of this cleared in 15 min and the remainder slowly. Twenty-five to 50 percent of the radioactivity subsequently distributed in the spleen, liver, and bone marrow, and these did not show significant change with time up to 48 hr post injection. The In-111 radioactivity administered as labeled leukocytes free from erythrocytes cleared from the circulating blood with a half-time of 7.5 hr. In three of 15 patients, the suspicion of inflammatory disease could not be confirmed, and in these a normal distribution of radioactivity was observed. In the remaining 12 patients, focal accumulation of radioactivity was detectable within 4 to 24 hr after administration, and subsequent confirmation of sepsis was obtained. From three such patients, samples of abscesses were recovered which showed markedly higher radioactivity than that in the same weight of blood.
D000038:Abscess / Q000000981:diagnostic imaging; D006801:Humans; D007204:Indium / Q000008:administration & dosage / Q000378:metabolism; D007249:Inflammation / Q000000981:diagnostic imaging; D007553:Isotope Labeling; D009504:Neutrophils; D015125:Oxyquinoline; D011868:Radioisotopes; D011877:Radionuclide Imaging; D013679:Technology, Radiologic
D011868:Radioisotopes; D007204:Indium; D015125:Oxyquinoline